Objective: Growing evidence suggests that vascular risk factors (VRF) contribute to cognitive decline. The aim of this study was to investigate the impact of VRF on the conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD) dementia.
progression of AD dementia, 10 but it remains unknown whether treating VRF can halt the progression from MCI to AD.
We have found that VRF were associated with the deterioration of AD in a Chinese cohort. 6 The present study was to investigate the effect of VRF and their treatment on the conversion from MCI to AD in a Chinese population.
METHODS Study subjects. Subjects were sampled from 10 randomly selected communities in the city of Chongqing. Eligibility requirements included subjects 1) who were 55 years and older and 2) who were long-term residents of these communities. Exclusion criteria were 1) a diagnosis of dementia, 2) a concomitant neurologic disorder potentially affecting cognitive function (e.g., severe Parkinson disease), 3) being unable to comply with the study assessment, 4) enduring mental illness, 5) drug abuse, 6) moving away or declining to participate.
Standard protocol approvals, registrations, and patient consents. This study was approved by the Institutional Review
Board of the Third Military Medical University, and all subjects and their caregivers provided informed consent.
Baseline screening. The baseline screening of the present study was performed during January 2004 and December 2004. In the selected communities, there was a total of 26,481 people aged 55 and above, of which 18,683 were screened at baseline. The 7, 798 subjects, who were not available at the time of screen (n ϭ 3,496) or declined to participate (n ϭ 4,302), did not significantly differ from the participants in age, sex, and occupation. Local elderly people were informed to attend the survey in the community centers at a certain time by posters, flyers, and a door-to-door notification. The subjects were interviewed individually in the community centers. For the 817 people who were unable to attend due to physical disabilities, or absent at the interview time, our staff went to their homes to perform the interview.
The following data were collected based on formal questionnaire and neuropsychological tests. These procedures were administered by trained interviewers composed of experienced neurologists, psychiatrists, and senior nurses. The agreement on data collection was found to be excellent based on the values of 0.92 for baseline screening questionnaire and 0.91 for neuropsychological tests.
Demographic data. These data included age, sex, educational level (lower educational level [illiteracy or primary school] and higher educational level [above secondary school]), and occupation (blue collar or white collar).
Smoking and drinking.
Smoking and drinking status were collected. The smoking status was classified as follows: past smokers who had quit smoking for at least 6 months; current smokers; nonsmokers. The drinking status was classified as daily drinking, weekly drinking, monthly drinking, occasional drinking, or never drinking as defined previously. 11 Clinical assessment. The medical history was collected from medical records and current medication based on formal question- naire. The data included prior head trauma and surgery, prior gas poisoning, schizophrenia, hypothyroidism, coronary heart diseases, atrial fibrillation, CVD defined by history, presence of focal neurologic signs or brain imaging including strategic or multiple lesions, or diffuse white matter lesions, or TIA, 12 chronic obstructive pulmonary disease, chronic hepatitis, chronic renal insufficiency, hypertension, diabetes mellitus, hypercholesterolemia, Parkinson disease, and regular use of nonsteroidal anti-inflammatory drugs. Blood pressure measurement and EKG were performed on site, and blood samples were collected for measuring hemogram, fasting glucose, thyroxin, creatinine, uric acid, transaminase, total cholesterol, and APOE4. Body mass index was measured. The subjects with abnormalities, which imply potential diseases that were not diagnosed before, were introduced to the hospital for further investigation. Diagnosis of diseases including anemia, hypothyroidism, hypertension, diabetes mellitus, hypercholesterolemia, obesity, coronary heart diseases, atrial fibrillation, CVD, chronic renal insufficiency, and chronic hepatitis were based on International Classification of Diseases, ninth revision.
Definition of VRF treatment.
With the similar methodology used in another study, 10 individual VRF was considered treated if it received its specific medication at baseline. The treatment of VRF included the following: use of diuretic, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, ␤-blocker, calcium channel blocker, or other antihypertensive medication for hypertension; oral antihyperglycemic or insulin for diabetes; statin and diet control for hypercholesterolemia; smoking or drinking were considered "treated" if the patient ceased smoking or drinking during the period of baseline interview. Subjects with VRF were divided into 3 groups: subjects with VRF untreated, subjects with all VRF treated, and subjects with some VRF treated.
Neuropsychological evaluation. The cognitive and functional status was assessed using the Chinese version of the Mini-Mental State Examination (MMSE) and instrumental Activities of Daily Living (ADL), which were validated previously in Chinese elderly people. 11, 13 The subjects who were abnormal in MMSE assessment were further administered neuropsychological tests, including Clinical Dementia Rating (CDR), 14 Fuld Object Memory Evaluation for detecting extensive cognitive dysfunction mainly composed of memory, 15 Rapid Verbal Retrieve for detecting the function of semantic memory, 16 Wechsler Adult Intelligence Scale (Digit Span and Block Design subtests) for evaluating immediate memory and function of graphical recognition, 17 Pfeiffer Outpatient Disability Questionnaire for assessing ability of social activities, 18 Hamilton Depression Rating Scale for measuring emotional status, 19 and Hachinski Ischemic Score (HIS) for evaluating significant vascular disease. 20
Diagnosis of MCI. The clinical diagnosis of MCI was made
according to the established Petersen criteria, 3 including subjective complaint of memory deficits, abnormal memory functioning for age, absence of dementia according to the diagnostic examination (CDR Ͻ0.5), and normal everyday functioning on ADL. The subjects with MCI with depressive disorder were excluded. 21
Global assessment of VRF in the subjects with MCI.
The subjects with MCI were considered to be with VRF as long as having one or more individual VRF (e.g., hypertension or diabetes). The subjects with MCI were divided into 2 groups: subjects with VRF or without.
Follow-up.
At baseline, 837 cases were enrolled into the present study. Subjects were followed up annually for 5 years from January 2005 to December 2009. Cognitive and functional status was first assessed using the same neuropsychological tests as baseline screening by examiners who were blinded to VRF information of the examinees. Then incidence of VRF was collected based on medical record or evaluation by doctors.
Diagnosis of AD dementia. The diagnosis of AD dementia was made following the protocol described in our previous studies. 13 In brief, dementia was diagnosed based on criteria modified from the DSM-IV. 22 The subjects with dementia were further subjected to brain CT or MRI. Diagnosis of AD dementia was made according to the criteria of National Institute of Neurological and Communicative Diseases and Stroke/AD and Related Disorders Association. 23 Diagnosis of vascular dementia (VaD) was based on the criteria of the National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN). 12 The differentiation of AD from VaD is based on the NINDS-AIREN criteria and HIS (HIS Յ4: AD, 4 Ͻ HIS Ͻ 7: mixed dementia, HIS Ն7: VaD). 20, 23, 24 AD was included in the present study.
Statistical analysis. In univariate analysis, baseline variables
were analyzed using t test for independent normally distributed continuous data, 2 test for categorical data, and Mann-Whitney U test for ordinal and categorical variables which were not normally distributed.
Cognitive and functional decline in terms of MMSE and ADL changes during the follow-up was analyzed to check for the interactions between time and VRF in mixed random effects regression models, in which a significant time effect indicates a change in MMSE or ADL score over time, and a significant interaction between VRF and time indicates a differential change in MMSE and ADL according to VRF. The association between VRF and incident AD dementia was estimated using Cox proportional hazard regression models in 2 steps: 1) global or individual VRF were included in the Cox regression model to analyze the association of VRF with incident AD dementia; 2) The association was further analyzed with adjustment for potential confounders, including age, sex, education, occupation, depressive symptoms, APOE4, and baseline MMSE and ADL scores. Similarly, the association of VRF treatment with incident AD dementia was calculated using Cox proportional hazard regression models in 2 steps: the global treatment of VRF (no treated, all treated, or some treated) or the treatment of individual VRF (treated or no treated) were included in the Cox model to assess the association of VRF treatment with incident AD dementia, which was further analyzed with adjustment for potential confounders, including age, sex, education, occupation, depressive symptoms, APOE4, baseline MMSE and ADL score, and propensity score. Variables for propensity score were age, sex, education level, occupation, baseline MMSE and ADL score, and number of VRF, and included stepby-step in a logistic regression model using an ␣ value of 0.2. 10 To reduce the bias caused by the changes of VRF treatment and its efficacy during the follow-up, intention-to-treat analysis strategy was used in multivariate analysis. 25 The statistical analyses were performed using SPSS 15.0 for Windows.
RESULTS
A total of 837 subjects with MCI were enrolled into the study at baseline, 638 (76.2%) subjects completed the follow-up, 140 (16.7%) dropped out, and 59 (7.0%) developed VaD (including 12 mixed dementia) and were excluded from the current analyses. Among the subjects dropped out, 16 died, 103 declined, and 21 moved away; 12 developed AD dementia and 3 developed VaD at or before the last visit ( figure) . At last, 298 (35.6%) developed AD dementia and 352 (42.1%) stayed in MCI. There were no other types of dementia detected in the present study. The conversion rate from MCI to AD dementia was 7.1% per year.
At baseline, there were 414 subjects with at least 1 VRF. During the follow-up, a total of 199 VRF occurred in the whole cohort, including hypertension (n ϭ 42), diabetes (n ϭ 36), hypercholesterolemia (n ϭ 22), myocardial infarction (n ϭ 18), atrial fibrillation (n ϭ 10), and CVD (n ϭ 71, 53 infarction, 18 hemorrhage, and 49 TIA); VRF occurred in 46 subjects who had no VRF at baseline. Baseline characteristics. The baseline characteristics of subjects who stayed in MCI and who converted to AD dementia are presented in table 1. Compared with subjects who stayed in MCI, those who converted to AD dementia were older, more frequently female, had lower education level, and blue collar occupation; had more VRF; and had a higher frequency of VRF including hypertension, diabetes, hypercholesterolemia, CVD, APOE4, current smoking, and daily drinking.
Association between VRF and the progression of MCI.
Results of mixed random effects regression analysis for VRF and each predictor are given in table 2. Globally, VRF was associated with faster decline in cognition (␤ ϭ Ϫ1.205 ؎ 0.129, p Ͻ 0.001) and function (␤ ϭ Ϫ1.111 Ϯ 0.182, p Ͻ 0.001) in terms of MMSE and ADL. Of the VRF variables, hypertension, diabetes, hypercholesterolemia, and CVD were associated with faster decline in cognition and function of MCI. Table 3 shows the Cox regression analysis for the association between VRF and incident AD dementia. Subjects with VRF had higher risk than the subjects without. Among the individual VRF, hypertension, diabetes, CVD, and hypercholesterolemia were associated with a higher risk of incident AD dementia. 
Association between VRF and AD conversion.

Association between VRF treatment and AD conversion.
To further confirm the association between VRF and incident AD dementia, additional Cox regression analyses were performed (table 4) . Compared with the subjects with VRF untreated, subjects with some or all VRF treated had lower risks of incident AD dementia. The risk of incident AD dementia in subjects with all VRF treated was lower than that in subjects with some VRF treated. When individual VRF were analyzed, treatment for hypertension, diabetes, and hypercholes-terolemia was associated with the lowered risk relative to nontreatment.
DISCUSSION Recent studies on the prevention and treatment of AD dementia have been focusing on identifying subjects at earlier stages of the disease. 2 MCI is the earliest symptomatic manifestation of AD, and it has a high rate of progression to dementia. 3, 26 The identification and subsequent management of risk factors at the MCI stage could be an important strategy for pre- venting and delaying progression to AD. In recent years, there has been evidence demonstrating that VRF were associated with MCI. 7, 8 Hypertension, 27, 28 diabetes, 29, 30 stroke, 29, 31 and hypercholesterolemia 27 were found to be associated with the development of MCI.
There are limited studies on the association between VRF and the progression of MCI. Recently stroke 8, 9 and atrial fibrillation 32 were found to be associated with the progression from MCI to dementia. However, it remains unknown whether untreated VRF hastens the conversion from MCI to AD, and, in particular, whether the treatment of VRF can halt the development of incident AD dementia. In the present prospective 5-year study, we enrolled 837 subjects with MCI in Chongqing, the biggest municipality in southwest China. 13 We found that VRF in either composite or individual measures hastened deterioration of MCI in terms of MMSE and ADL score changes. With the comparable methodologies used in other studies, 9, 32 we found that VRF were associated with increased risk of incident AD dementia, while treatment of VRF was associated with reduced risk.
The prevalence of MCI in subjects aged 55 or over was 5.2%, and the annual conversion rate from MCI to AD is 7.1% in our cohort from southwest China. These values are comparable to those observed in western populations. 8, 33 This is also in accordance with a recent study that the prevalence of AD in China is similar to that in western countries. 34 The mechanism for the effect of VRF on the progression from MCI to AD dementia remains unclear. It is likely that the effect of VRF is entirely through cerebrovascular mechanisms and simply lowered the threshold at which AD pathology produced more symptoms. Some evidence suggests that several VRF can directly affect the metabolism of amyloid-␤ (A␤) which indicates that VRF might play a pivotal or causal role in the pathogenesis of AD. Hypertension was found to significantly increase A␤ level in the brain of APPswe transgenic mice. 35 Type 2 diabetes stimulates A␤ production and inhibits its degradation in the brain of APPswe mice by activating ␥ secretase and inhibiting insulin-degrading enzyme (IDE). 36 Cerebral ischemia resulted from CVD increases the level and activity of ␤ secretase and alters IDE level to induce A␤ deposits. 37 Hypercholesterolemia promotes A␤ production by activating the activities of ␤ and ␥ secretases. 38 The increased A␤ burden resulted from VRF may ultimately promote the development of AD. However, these proposed mechanisms are more speculative and need further studies.
A recent study suggests that treatment of VRF is associated with slower cognitive decline in AD. 10 Whether the treatment of VRF can delay progression in subjects with MCI is unknown. We found that VRF treatment was associated with lower risk of incident AD dementia in a treatment-status-dependent pattern, in which the group with all VRF treated received lower risk of AD conversion relative to the groups with some VRF treated or untreated. Consistently, treatment for individual VRF including hypertension, diabetes, and hypercholesterolemia was independently associated with the lower risk of AD conversion.
Our study is an observational study which has inherent substantial limitations. 10 VRF changed during follow-up in a relatively small part of subjects who had no VRF at baseline (n ϭ 46, 7.1%). In addition, subjects treated for their VRF might differ from subjects with VRF untreated in severity and number of VRF, socioeconomic status, and other factors. The treatment status and its efficacy could also have changed during the follow-up. Thus propensity score was used to correct the bias produced by the probability of each patient to be treated and treatment compliance, 10, 39 and intention-to-treat analysis strategy was used to reduce the bias induced by changes of VRF and their treatment during follow-up, 25 but these factors could also have biased the results. We excluded subjects with clinically diagnosed VaD, who in fact, might have had both AD pathology and cerebrovascular disease. Had these subjects been included, the benefits of treatment of VRF might have been larger. A definitive answer to whether VRF treatment reduced progression in subjects with MCI would require randomized controlled trials. With these limitations in mind, our study provides new evidence to support the possible etiologic roles of VRF in the progression from MCI to AD dementia.
